Accedi

Bibliografie tematiche / Advanced therapy medicine / Articoli di riviste

Articoli di riviste sul tema "Advanced therapy medicine"

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Advanced therapy medicine.

Autore: Grafiati

Pubblicato: 20 luglio 2024

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Advanced therapy medicine".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

Mayr, Nina A., Simon S. Lo, Murat Alp Oztek, Charles G. Colip e William T. C. Yuh. "Advanced Neuroimaging for Advanced Radiation Therapy". Topics in Magnetic Resonance Imaging 28, n. 2 (aprile 2019): 35–36. http://dx.doi.org/10.1097/rmr.0000000000000200.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Zhao, Kai, Ying Na e Hui-Min Xu. "Advances in translational therapy for locally advanced gastric cancer". World Journal of Clinical Cases 11, n. 11 (16 aprile 2023): 2405–11. http://dx.doi.org/10.12998/wjcc.v11.i11.2405.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Coleman III, W. P. "Advanced Dermatologic Therapy II". JAMA: The Journal of the American Medical Association 287, n. 5 (6 febbraio 2002): 646. http://dx.doi.org/10.1001/jama.287.5.646.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Hanna, E., C. Marre e M. Toumi. "PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSIS". Value in Health 21 (ottobre 2018): S209—S210. http://dx.doi.org/10.1016/j.jval.2018.09.1242.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Gourbat, J. P. "Compression Therapy in Aeronautic Medicine". Phlebology: The Journal of Venous Disease 15, n. 3-4 (dicembre 2000): 178–81. http://dx.doi.org/10.1177/026835550001500319.

Testo completo

Abstract (sommario):

Aim: To review the influences of air and space travel on the venous side of the circulation and to assess the consequences for air and space travellers. Method: A review of current literature in the field of aeronautical travel has been conducted, with particular reference to the effects on the venous system and use of compression garments. Synthesis: The venous system is particularly sensitive to gravitational and pressure changes encountered during air and space travel due to the low pressures normally present in this part of the circulation. The symptoms experienced by air crew may be countered by the use of venous compression stockings, amongst other measures. More sophisticated techniques are required for fighter aviation and space flights. Aircraft and spacecraft travel in a hostile environment in which it is not possible for man to survive without sophisticated layers of protection. In addition, forces of acceleration generated by aircraft flight combine with those of the environment hazarding the safety and the health of navigators. Continuing technical advances allow increased performance towards ever greater speed, better acceleration, a greater range of action and longer periods of time in space. Conclusion: Increasingly, the limiting factor in air and space travel appears to be man, who has difficulty in tolerating the environment to which he is exposed. The immediate risk is loss of consciousness and in time there is the risk of health deterioration. The cardiovascular system as a whole is at the centre of this problem and seems to be one of the limiting factors in the design of more advanced aircraft, especially those used for military purposes.

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Mie, Takafumi, Takashi Sasaki, Takeshi Okamoto, Takaaki Furukawa, Tsuyoshi Takeda, Akiyoshi Kasuga, Masato Ozaka e Naoki Sasahira. "Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine". Cancers 16, n. 5 (22 febbraio 2024): 879. http://dx.doi.org/10.3390/cancers16050879.

Testo completo

Abstract (sommario):

First-line chemotherapy has been established for advanced biliary tract cancer (BTC). However, few treatment options are available as second-line treatment. Advances in comprehensive genomic analysis revealed that nearly half of patients with BTC harbor targetable genetic alterations such as fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), BRAF, human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI)-high, neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), and poly (adenosine diphosphate-ribose) polymerase (PARP). This review summarizes currently available options in precision medicine and clinical trials for patients with advanced BTC.

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Del Portillo, Isabel, Christine Sesanto, Magdalena Parys e Juan Carlos Serra. "Radiation therapy in veterinary medicine: a practical review". Companion Animal 25, n. 7 (2 agosto 2020): 1–15. http://dx.doi.org/10.12968/coan.2019.0056.

Testo completo

Abstract (sommario):

Radiotherapy is a treatment modality based on the use of high-energy rays to kill neoplastic cells, which has become an integral therapeutic tool in veterinary medicine. Radiotherapy may be an effective treatment for tumours that are not easily managed with surgery or with chemotherapy, even for patients with advanced-stage neoplasia. Novel uses of radiotherapy include rescue therapy for specific benign conditions that are refractory to conventional therapy. Acute and late toxicities depend on the prescribed protocol as well as sensitivity and volume of the normal tissue in or near the radiation field. The potential risks associated with the treatment should be fully discussed with owners before starting radiotherapy. New hardware and software technology has drastically advanced the ability to precisely target tumours, improving treatment efficacy and safety.

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Sai, Duc Loc, Jieun Lee, Duc Long Nguyen e Young-Pil Kim. "Tailoring photosensitive ROS for advanced photodynamic therapy". Experimental & Molecular Medicine 53, n. 4 (aprile 2021): 495–504. http://dx.doi.org/10.1038/s12276-021-00599-7.

Testo completo

Abstract (sommario):

AbstractPhotodynamic therapy (PDT) has been considered a noninvasive and cost-effective modality for tumor treatment. However, the complexity of tumor microenvironments poses challenges to the implementation of traditional PDT. Here, we review recent advances in PDT to resolve the current problems. Major breakthroughs in PDTs are enabling significant progress in molecular medicine and are interconnected with innovative strategies based on smart bio/nanomaterials or therapeutic insights. We focus on newly developed PDT strategies designed by tailoring photosensitive reactive oxygen species generation, which include the use of proteinaceous photosensitizers, self-illumination, or oxygen-independent approaches. While these updated PDT platforms are expected to enable major advances in cancer treatment, addressing future challenges related to biosafety and target specificity is discussed throughout as a necessary goal to expand the usefulness of PDT.

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Goula, Aspasia, Vasiliki Gkioka, Efstathios Michalopoulos, Michalis Katsimpoulas, Michel Noutsias, Eirini Faidra Sarri, Catherine Stavropoulos e Alkiviadis Kostakis. "Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine". Journal of Clinical Medicine Research 12, n. 12 (2020): 780–86. http://dx.doi.org/10.14740/jocmr3964.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Vaggelas, Annegret, e Diane Seimetz. "Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation". Therapeutic Innovation & Regulatory Science 53, n. 3 (maggio 2019): 364–73. http://dx.doi.org/10.1177/2168479018779373.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

11

Schad, F. "Advanced pancreatic cancer: An integrative therapy concept in anthroposophic medicine". European Journal of Integrative Medicine 2, n. 4 (dicembre 2010): 165–66. http://dx.doi.org/10.1016/j.eujim.2010.09.214.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

Robinson, Robert. "Advanced Therapy in Epilepsy". European Journal of Paediatric Neurology 14, n. 5 (settembre 2010): 464–65. http://dx.doi.org/10.1016/j.ejpn.2010.04.001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Sahajwani, Ritika, Manish Srivastava, Anamika Srivastava, Chanchal Parashar, Agrima Singh, Prabhjot Kaur e Jaya Dwivedi. "Advanced Materials in Cancer Therapy". Green Chemistry & Technology Letters 7, n. 2 (20 dicembre 2021): 01–17. http://dx.doi.org/10.18510/gctl.2021.721.

Testo completo

Abstract (sommario):

The overview of this review article depends on the various techniques of formation of silver nanoparticles and different application take place in medicinal point of view. The branch of nanotechnology plays an important role in medical science research. In this different nanoparticle is synthesized which have various application in gene delivery, drug delivery and reduce the toxic effect of drugs in the human body and also act as an antibacterial in pharmaceutical industries. In recent days silver nanoparticles have had an important role due to their optical and catalytic properties. A large number of different particles or methods are used to prepare the different shapes of silver nanoparticles used in drug delivery. Different shapes of nanoparticles have increased their demand in various researches depend on medicinal uses. Silver nanoparticle preparation can be studied by 3 techniques related to irradiations, chemicals, bacteria, fungi, and plants. Nanomedicine have a large number of advantages in treating various chronic diseases by using biological agents, chemotherapeutic agents, and used to deliver the drug to a specific site of the body. A silver nanoparticle is prepared for detection tool to detect the adverse effect of diseases on the target cell. Nanoparticles are used in cancer therapy to remove the damaged cell of the body.

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Qiu, Jiajun. "Music Therapy and Advanced Dementia". International Journal of Clinical and Experimental Medicine Research 6, n. 4 (17 novembre 2022): 419–23. http://dx.doi.org/10.26855/ijcemr.2022.10.016.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Hjortshøj, Cristel S., Annette S. Jensen e Lars Søndergaard. "Advanced Therapy in Eisenmenger Syndrome". Cardiology in Review 25, n. 3 (2017): 126–32. http://dx.doi.org/10.1097/crd.0000000000000107.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Xu, Weiru, Guowang Yang, Yongmei Xu, Qing Zhang, Qi Fu, Jie Yu, Mingwei Yu et al. "The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer". Evidence-Based Complementary and Alternative Medicine 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/278917.

Testo completo

Abstract (sommario):

Lung cancer has become the leading cause of cancer deaths, with nonsmall cell lung cancer (NSCLC) accounting for around 80% of lung cancer cases. Chemotherapy is the main conventional therapy for advanced NSCLC. However, the disease control achieved with classical chemotherapy in advanced NSCLC is usually restricted to only a few months. Thus, sustaining the therapeutic effect of first-line chemotherapy is an important problem that requires study. Maintenance therapy is given for patients with advanced NSCLC if three is no tumor progression after four to six cycles of first-line platinum-based chemotherapy. However, selection of appropriate maintenance therapy depends on several factors, while traditional Chinese medicine (TCM) as maintenance therapy is recommended for all kinds of patients. It has been demonstrated that TCM can prolong the survival time, improve the quality of life (QOL), and reduce the side effects for advanced NSCLC. Although the trials we searched about TCM serving as maintenance therapy is only 9 studies, the results indicate TCM can prolong the progression free survival (PFS) and improve the QOL. So it is possible for TCM to be as maintenance therapy for advanced NSCLC. More rigorous trials are required to further verify its efficacy.

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Sulciner, Megan L., Stanley W. Ashley e George Molina. "Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma". Journal of Clinical Medicine 11, n. 16 (19 agosto 2022): 4866. http://dx.doi.org/10.3390/jcm11164866.

Testo completo

Abstract (sommario):

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies in the United States. Improvements in imaging have permitted the categorization of patients according to radiologic involvement of surrounding vasculature, i.e., upfront resectable, borderline resectable, and locally advanced disease, and this, in turn, has influenced the sequence of chemotherapy, surgery, and radiation therapy. Though surgical resection remains the only curative treatment option, recent studies have shown improved overall survival with neoadjuvant chemotherapy, especially among patients with borderline resectable/locally advanced disease. The role of radiologic imaging after neoadjuvant therapy and the potential benefit of adjuvant therapy for borderline resectable and locally advanced disease remain areas of ongoing investigation. The advances made in the treatment of patients with borderline resectable/locally advanced disease are promising, yet disparities in access to cancer care persist. This review highlights the significant advances that have been made in the treatment of borderline resectable and locally advanced PDAC, while also calling attention to the remaining challenges.

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Bogachev, Yu V., A. V. Nikitina e M. N. Shishkina. "Advanced Methods of Magnetic Resonance Theranostics". LETI Transactions on Electrical Engineering & Computer Science 16, n. 1 (2023): 5–24. http://dx.doi.org/10.32603/2071-8985-2023-16-1-5-24.

Testo completo

Abstract (sommario):

The combination of high-resolution and high-sensitivity diagnostic methods with the therapy of socially significant diseases under the influence of various physical fields, methods or substances is the basis of new intensively developed areas of modern medicine. This review article analyzes advanced methods of magnetic resonance (MR) theranostics, such as MRI-guided laser therapy, MRI tracking in stem cell therapy, MRguided therapy using MRI-theranostic agents based on magnetic nanoparticles, transcranial magnetic stimulation combined with functional MRI (TMS/fMRI). The paper presents both research materials and examples of clinical applications of these methods.

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Ghafoor, Robia. "Stem Cell Role in Regenerative Dental Medicine". Annals of Jinnah Sindh Medical University 8, n. 2 (30 dicembre 2022): 45–46. http://dx.doi.org/10.46663/ajsmu.v8i2.45-46.

Testo completo

Abstract (sommario):

Regeneration therapies have widely permeated advanced research that aims to reproduce and repair a lost or damaged organ or tissue in order to restore the function and architecture as close to its original state as possible. Tissue engineering refers to the process of regeneration using techniques such as scaffold based cell cultures, stem cell therapy, and biomolecular signaling.

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Javan, Hanna, Farshid Dayyani e Nadine Abi-Jaoudeh. "Therapy in Advanced Hepatocellular Carcinoma". Seminars in Interventional Radiology 37, n. 05 (dicembre 2020): 466–74. http://dx.doi.org/10.1055/s-0040-1719187.

Testo completo

Abstract (sommario):

AbstractTreatment of advanced hepatocellular carcinoma (HCC) is challenging. Several randomized clinical trials are investigating the efficacy of systemic therapy, immunotherapy, and locoregional therapy as monotherapy or combined with other modalities in the treatment of HCC. Systemic therapy is the preferred treatment in advanced disease. To date, multiple first-line and second-line agents received Food and Drug Administration approval. For over a decade, sorafenib was the only first-line agent. In May 2020, combination of atezolizumab and bevacizumab has been approved as a first-line systemic regimen. Lenvatinib is another first-line agent that has multikinase activity. Second-line agents include cabozantinib, regorafenib, ramucirumab, and nivolumab. Adoptive cell transfer therapy is a highly specific immunotherapy that has shown antitumor activity against HCC. Oncolytic viruses are genetically modified viruses that infect cancer cells and induce apoptosis. Locoregional therapies such as transarterial chemoembolization and radioembolization have shown a potential benefit in selected patients with advanced HCC. In this review, we aim to summarize the treatment options available for advanced HCC.

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Taghizadeh, Hossein, Matthias Unseld, Martina Spalt, Robert M. Mader, Leonhard Müllauer, Thorsten Fuereder, Markus Raderer et al. "Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI". Journal of Personalized Medicine 10, n. 4 (23 ottobre 2020): 188. http://dx.doi.org/10.3390/jpm10040188.

Testo completo

Abstract (sommario):

Advanced therapy-refractory solid tumors bear a dismal prognosis and constitute a major challenge in offering effective treatment strategies. In this real-world retrospective analysis of our precision medicine platform MONDTI, we describe the molecular profile of 554 patients diagnosed with 17 different types of advanced solid tumors after failure of all standard treatment options. In 304 cases (54.9% of all patients), a molecular-driven targeted therapy approach could be recommended, with a recommendation rate above 50% in 12 tumor entities. The three highest rates for therapy recommendation per tumor classification were observed in urologic malignancies (90.0%), mesothelioma (78.6%), and male reproductive cancers (71.4%). Tumor type (p = 0.46), expression of p-mTOR (p = 0.011), expression of EGFR (p = 0.046), and expression of PD-L1 (p = 0.023) had a significant impact on the targeted therapy recommendation rate. Therapy recommendations were significantly more often issued for men (p = 0.015) due to gender-specific differences in the molecular profiles of patients with head and neck cancer and malignant mesothelioma. This analysis demonstrates that precision medicine was feasible and provided the basis for molecular-driven therapy recommendations in patients with advanced therapy refractory solid tumors.

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Folkmanis, Kristofs, Elizabete Junk, Evelīna Merdane, Valdis Folkmanis, Inese Folkmane e Sergejs Isajevs. "Current Trends in Advanced Prostate Cancer Medical Setting". Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 76, n. 2 (1 aprile 2022): 168–80. http://dx.doi.org/10.2478/prolas-2022-0027.

Testo completo

Abstract (sommario):

Abstract Treatment of advanced and metastatic prostate carcinoma (PCa) is still challenging and changing in the era of personalised medicine. Combination therapies with docetaxel and new anti-hormonal substances lead to improved OS (overall survival) in a broad group of patients with metastatic hormone sensitive prostate carcinoma (mHSPCa). Addition of docetaxel or an androgen receptor targeting agent (ARTA) with abiraterone plus prednisolone, with apalutamide or with enzalutamide leads to a significant improvement in OS and an increase in the time to transition to castration resistance. The choice of therapy sequence in advanced PCa should be based, among other things, on the side-effect profiles of the substances and patient’s preferences. Within metastatic castration resistant prostate carcinoma (mCRPCa) setting, the therapy with abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223 is approved and indicated in Europe. Respectively, five substances are available, each of which has led to a significant increase in survival time in phase III studies. The optimal therapy sequence in the mCRPCa stage is still unclear. The current trend in personalised medicine in the next decade in therapy, regarding prostate carcinoma, are poly(ADP)-ribose polymerase (PARP) inhibitors, which are and will be available as an effective therapy option for patients with mutations in DNA repair genes. The most important question is when and how patients should be tested for mutations in DNA repair genes and to which line of therapy will PARP inhibitors belong.

Gli stili APA, Harvard, Vancouver, ISO e altri

23

向, 妍. "Recent Advances in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer". Advances in Clinical Medicine 13, n. 04 (2023): 7026–32. http://dx.doi.org/10.12677/acm.2023.134983.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

位, 凤. "Advances in Anti-Angiogenesis Therapy for Middle and Advanced Cervical Cancer". Advances in Clinical Medicine 13, n. 08 (2023): 13499–504. http://dx.doi.org/10.12677/acm.2023.1381884.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Vuletić, Vladimira. "Sex Differences in the Therapy of Advanced Movement Disorders". Archives of Psychiatry Research 59, n. 1 (20 febbraio 2023): 107–14. http://dx.doi.org/10.20471/may.2023.59.01.14.

Testo completo

Abstract (sommario):

The influence of sex differences in movement disorders is still under-recognized. There are significant sex differences in the pathophysiology, epidemiology, clinical manifestations, and treatments outcome of many of movement disorders especially Parkinson’s disease. Importance of sex specific differences in invasive treatment outcomes emphasize the importance of their considering when devising patient’s individual management strategies. Increased recognition and future prospective studies specifically addressing sex differences in invasive treatments’ outcomes may help and provide a tailored therapeutic and precision medicine approach to movement disorders. We highlight the most relevant invasive treatment’s effects in advanced movement disorders that differ between men and women. But also, the differences in selection of invasive methods. Increased recognition of sex differences and their impact on treatment of advanced phase of movement disorders, that are very disabling, is very important for future studies and precise and personalized medicine. In this article, we provide a review of sex- related differences in treatment of advanced movement disorders, mostly Parkinson’s diseases.

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Nagy, Viktor. "Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial". Orvosi Hetilap 148, n. 39 (1 settembre 2007): 1839–42. http://dx.doi.org/10.1556/oh.2007.28216.

Testo completo

Abstract (sommario):

Az új évezredben a hipertónia és a cukorbaj fenyegeti világszerte a leginkább a populáció egészségi állapotát. A cukorbaj (hemoglobin-A1c < 6,5%) és a hipertónia (vérnyomás < 130/80 Hgmm) együttes beállítása központi helyet foglal el a cukorbetegek macro- és microvascularis betegségének megelőzésében. Az „Action in Diabetes and Vascular Disease: PreterAx and DiamicroN” tanulmány az első nagy prospektív, multicentrikus, randomizált, kontrollált vizsgálat, amelyben 2 × 2 faktoriális elrendezésben állapítják meg a vérnyomáscsökkentés (perindopril/indapamid kombináció) és a gliclazide-MR-en alapuló intenzív vércukor-beállítás hasznosságát a macro- és microvascularis kimenetelre.

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Zonies, David, e Matthias Merkel. "Advanced extracorporeal therapy in trauma". Current Opinion in Critical Care 22, n. 6 (dicembre 2016): 578–83. http://dx.doi.org/10.1097/mcc.0000000000000366.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Vertkin, Vertkin A. L. "Advanced training of outpatient doctors is a national health care priority". Therapy 6_2022 (23 settembre 2022): 7–10. http://dx.doi.org/10.18565/therapy.2022.6.7-10.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

29

Vaughn, David J. "Hormonal Therapy for Advanced Prostate Cancer". Annals of Internal Medicine 132, n. 7 (4 aprile 2000): 584. http://dx.doi.org/10.7326/0003-4819-132-7-200004040-00011.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

García-González, Javier, Sonia Marhuenda-Castillo, Sheila Romero-Carretero e Jesús Beltrán-García. "New era of personalized medicine: Advanced therapy medicinal products in Europe". World Journal of Immunology 11, n. 1 (24 luglio 2021): 1–10. http://dx.doi.org/10.5411/wji.v11.i1.1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Schoeneich, G., S. C. Müller e H. Palmedo. "Indication for nuclear medicine therapy in advanced cancer of the prostate". Der Urologe 37, n. 2 (marzo 1998): 162–66. http://dx.doi.org/10.1007/s001200050167.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Wang, Xiaofei, Wilson W. Bryan e Lei Xu. "Breakthrough Therapy Designation & Regenerative Medicine Advanced Therapy Designation Programs in Cellular & Gene Therapies". Cell and Gene Therapy Insights 4, n. 6 (17 luglio 2018): 563–71. http://dx.doi.org/10.18609/cgti.2018.046.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Lee, Yun-Gyoo, Hyun-Il Gil, Soo Jeong Kim, Hyunjoo Lee, Heerim Nam, Soo-Youn Ham e Du-Young Kang. "Targeted Therapy of Advanced Non-Small Cell Lung Cancer". Korean Journal of Medicine 99, n. 2 (1 aprile 2024): 96–103. http://dx.doi.org/10.3904/kjm.2024.99.2.96.

Testo completo

Abstract (sommario):

Lung cancer is the leading cause of cancer death in Republic of Korea. After their initial diagnosis, only 10-20% of patients with advanced non-small cell lung cancer (NSCLC) survive for 5 years of longer. Given enormous advances in therapeutics such as novel targeted therapies and immunotherapies, survival rates are improving for advanced patients with NSCLC; 5-year survival rates range from 15% to 50%, contingent upon the biomarker. Detection of the specific molecular alteration as biomarker is thus crucial for identifying subgroups of NSCLC that contain therpapeutically targetable oncogenic drivers. This review examines the process of diagnosing lung adenocarcinoma with dominant biomarkers in order to customize treatment with appropriate targeted therapy.

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Kim, Jenny J., e Brian I. Rini. "Recent advances in molecularly targeted therapy in advanced renal cell carcinoma". Therapy 6, n. 3 (maggio 2009): 309–20. http://dx.doi.org/10.2217/thy.09.16.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

35

Kumar Das, Dibash. "Maintenance Therapy for Advanced Urothelial Cancer". Oncology Times 43, n. 23 (5 dicembre 2021): 1,18–18. http://dx.doi.org/10.1097/01.cot.0000804736.62543.74.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

Buzaid, Antonio C., Scott M. Lippman e Thomas P. Miller. "Salvage therapy of advanced hodgkin's disease". American Journal of Medicine 83, n. 3 (settembre 1987): 523–32. http://dx.doi.org/10.1016/0002-9343(87)90766-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

Sasson, Aaron R., John P. Hoffman, Eric Ross, Neal J. Meropol, Christine E. Szarka, Gary Freedman, Wayne Pinover, James F. Pingpank e Burton L. Eisenberg. "Trimodality Therapy for Advanced Gallbladder Cancer". American Surgeon 67, n. 3 (marzo 2001): 277–84. http://dx.doi.org/10.1177/000313480106700315.

Testo completo

Abstract (sommario):

We conducted a retrospective review of all patients who underwent surgical extirpation for stage IN, stage IV, or recurrent carcinoma of the gallbladder. Between 1991 and 1999 ten patients underwent surgical resection for advanced gallbladder cancer. All patients received adjuvant therapy either pre- or postoperatively. Radiotherapy was used in all patients and chemotherapy in 90 per cent of patients. Two patients subsequently underwent resection for locally recurrent disease. An additional patient with stage II disease initially was also treated surgically for a local recurrence. Surgical management involved cholecystectomy and resection of various amounts of liver surrounding the gallbladder bed and regional lymphadenectomy. Contiguously involved structures were resected en bloc. Resection of recurrent disease included excision of all gross tumor. The median overall survival excluding the one 30-day mortality was 53.6 months (range 8–73 months). Four patients have survived 4 or more years, and currently four patients are alive and disease free at 73, 49, 33, and 8 months. Median disease-free interval after each resection of recurrent disease was 13.8 months (range 4–28 months). We conclude that trimodality therapy in selected patients with stage III, IV, or recurrent carcinoma of the gallbladder is possible and may result in prolonged survival.

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Cox, Jenny. "Radiation therapy advanced practice – commentary". Journal of Medical Radiation Sciences 60, n. 4 (20 novembre 2013): 157–58. http://dx.doi.org/10.1002/jmrs.29.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

39

Kato, Harubumi. "Our Experience With Photodynamic Diagnosis and Photodynamic Therapy for Lung Cancer". Journal of the National Comprehensive Cancer Network 10, Suppl_2 (ottobre 2012): S—3—S—8. http://dx.doi.org/10.6004/jnccn.2012.0170.

Testo completo

Abstract (sommario):

The diagnosis of lung cancer was significantly enhanced by the development of the fiberoptic bronchoscope in 1965. Since then, advances in photosensitizers and light sources have brought photodynamic medicine into the light. This article offers an historic overview of the emergence of photodynamic medicine through the perspective of a pioneer with more than 30 years’ experience. Along with a discussion of photodynamic diagnosis of lung cancers via optical coherence tomography, the curative, palliative, and neoadjuvant roles of photodynamic therapy for early and advanced lung cancers are explored. An emerging strategy of using PDM to treat peripheral early-stage lung tumors is briefly discussed.

Gli stili APA, Harvard, Vancouver, ISO e altri

40

Ferreira-Gonzalez, Andrea. "Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition". Journal of Applied Laboratory Medicine 5, n. 5 (1 settembre 2020): 1076–89. http://dx.doi.org/10.1093/jalm/jfaa117.

Testo completo

Abstract (sommario):

Abstract Background Even though endocrine therapy is often initially successful in treating advanced breast cancer, most patients inevitably face disease progression. In advanced hormone receptor–positive (HR+) breast cancer, activation of the PI3K downstream pathway is a critical feature of the mechanism of endocrine resistance. A significant recent advance in treating HR+ advanced breast cancer has been the recent introduction of PI3K inhibitor (PI3Ki) for the treatment of patients with HR+, HER2-negative (HER2−) advanced or metastatic breast cancer that harbors PIK3CA mutations. A value proposition concept was applied to assess the potential benefits of cell-free tumor DNA (ctDNA) testing to identify patients who might respond to PI3Ki treatment. Content By applying the framework of the value proposition to >35 publications, in addition to recommendations from professional organizations, it was evident that robust clinical evidence exists to support the role of ctDNA PIK3CA mutation evaluation in identifying patients with advanced breast cancer who could benefit from PI3Ki treatment. Summary Detection of PIK3CA gene mutations in HR+HER2− advanced breast cancer patients allows for the identification of patients who might benefit from more effective personalized treatment with molecularly targeted drugs.

Gli stili APA, Harvard, Vancouver, ISO e altri

41

Sullo, Francesco, Alessandro Passardi, Chiara Gallio, Chiara Molinari, Giorgia Marisi, Eleonora Pozzi, Leonardo Solaini e Alessandro Bittoni. "Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer". Journal of Clinical Medicine 13, n. 9 (26 aprile 2024): 2562. http://dx.doi.org/10.3390/jcm13092562.

Testo completo

Abstract (sommario):

Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, distant tumor recurrence remains a concern, prompting the exploration of total neoadjuvant therapy (TNT) as a comprehensive treatment strategy. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, potentially revolutionizing neoadjuvant regimens. Nonoperative management (NOM) represents a viable alternative post-neoadjuvant therapy for selected patients achieving complete clinical response (cCR). Additionally, monitoring minimal residual disease (MRD) using circulating tumor DNA (ctDNA) emerges as a non-invasive method for the assessment of treatment response. This review synthesizes current evidence on TNT, ICIs, NOM, and ctDNA, elucidating their implications for rectal cancer management and highlighting avenues for future research and clinical application.

Gli stili APA, Harvard, Vancouver, ISO e altri

42

Horgan, Denis, Andres Metspalu, Marie-Christine Ouillade, Dimitrios Athanasiou, John Pasi, Oumeya Adjali, Patrick Harrison et al. "Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion". Biomedicine Hub 5, n. 3 (3 dicembre 2020): 1–23. http://dx.doi.org/10.1159/000511678.

Testo completo

Abstract (sommario):

Recent advances in biomedicine are opening the door to new approaches, and treatment and prevention are being transformed by novel medicines based on genetic engineering, innovative cell-based therapies and tissue-engineered products, and combinations of a medical device with embedded cell or tissue components. These advanced therapy medicinal products (ATMPs) hold one of the keys to making a reality of genuinely personalised medicine. There are an estimated 450 companies across the globe working on the development of gene therapies and more than 1,000 clinical trials underway worldwide, and some 20–30 new ATMPs filings are expected in Europe annually over the next 5 years. But challenges confront the sector, complicating the translation from research into patient access. Scientific, clinical development and regulatory issues are compounded by limited experience with clinical and commercial use, limited manufacturing know-how, high costs, and difficulties in accessing development funding and investment. Pricing and reimbursement and market access issues are an additional challenge, particularly in Europe, where unfamiliarity with the technology and uncertainty over the use of real-world evidence induce caution among clinicians, health technology assessment bodies and payers. There is a need for a review of the suitability of the regulatory and market access framework for these products, focused development of data, public/private partnerships, and fuller collaboration governments, doctors, insurers, patients, and pharmaceutical companies. This paper makes specific recommendations for all stakeholders, ranging from early dialogue on potential products, linking of clinical data and patient registries or standardisation of control frameworks, to a comprehensive approach to evidence generation, assessment, pricing, and payment for ATMPs.

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Rinke, Anja, Christoph J. Auernhammer, Lisa Bodei, Mark Kidd, Sebastian Krug, Rita Lawlor, Ilaria Marinoni et al. "Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?" Gut 70, n. 9 (10 marzo 2021): 1768–81. http://dx.doi.org/10.1136/gutjnl-2020-321300.

Testo completo

Abstract (sommario):

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors are treatment options but predictive tools are lacking. The inability to identify clonal heterogeneity and define critical oncoregulatory pathways prior to therapy, restrict therapeutic efficacy as does the inability to monitor disease status in real time. Chemotherapy in the poor prognosis NEN G3 group, though associated with acceptable response rates, only leads to short-term tumour control and their molecular biology requires delineation to provide new and more specific treatment options.The future requires an exploration of the NEN tumour genome, its microenvironment and an identification of critical oncologic checkpoints for precise drug targeting. In the advance to personalised medical treatment of patients with GEPNEN, clinical trials need to be based on mechanistic and multidimensional characterisation of each tumour in order to identify the therapeutic agent effective for the individual tumour.This review surveys advances in NEN research and delineates the current status of translation with a view to laying the basis for a genome-based personalised medicine management of advanced GEPNEN.

Gli stili APA, Harvard, Vancouver, ISO e altri

44

Burke, James F. "Radiometals in Diagnosis and Therapy". Metal-Based Drugs 4, n. 3 (1 gennaio 1997): 153–58. http://dx.doi.org/10.1155/mbd.1997.153.

Testo completo

Abstract (sommario):

Radiometals are the mainstay of both diagnostic and therapeutic nuclear medicine because the choice of radionuclide is primarily dictated by nuclear decay characteristics rather than chemistry. T99mc is the most frequently used diagnostic radionuclide and requires coordination in a diversity of chemical disguises to permit imaging of a variety of tissues and disease states. Therapeutic nuclear medicine is less advanced but can provide significant benefits provided the radionuclide is accurately targetted.

Gli stili APA, Harvard, Vancouver, ISO e altri

45

Orlova, N. V., e L. I. Ilyenko. "Extemporal production of medicines – advantages and prospects". Medical alphabet, n. 13 (18 ottobre 2023): 7–10. http://dx.doi.org/10.33667/10.33667/2078-5631-2023-13-7-10.

Testo completo

Abstract (sommario):

Extemporal drugs are an important component in pharmaceutical practice, allowing the provision of dosage forms or dosages that are not commercially available, and the personification of drug therapy. These drugs are most in demand in pediatrics, gerontology, oncology, palliative medicine, dermatology. A number of measures are necessary for the introduction of extemporal production of medicines into modern practical medicine: changing regulatory legal acts regulating the manufacture of extemporal medicines; improvement of modern methods of quality control; updating of the collection of extemporal medicines; ensuring the introduction of the use of extemporal medicines in practical healthcare; modernization of pharmacy equipment; organization of advanced training of medical and pharmaceutical specialists in the field of prescribing, manufacturing complex dosage forms in pharmacies and control of their production.

Gli stili APA, Harvard, Vancouver, ISO e altri

46

Gupta, Rohit, e Robert P. Baughman. "Advanced Pulmonary Sarcoidosis". Seminars in Respiratory and Critical Care Medicine 41, n. 05 (10 agosto 2020): 700–715. http://dx.doi.org/10.1055/s-0040-1709495.

Testo completo

Abstract (sommario):

AbstractAt least 5% of sarcoidosis patients die from their disease, usually from advanced pulmonary sarcoidosis. The three major problems encountered in advanced pulmonary sarcoidosis are pulmonary fibrosis, pulmonary hypertension, and respiratory infections. Pulmonary fibrosis is the result of chronic inflammation, but other factors including abnormal wound healing may be important. Sarcoidosis-associated pulmonary hypertension (SAPH) is multifactorial including parenchymal fibrosis, vascular granulomas, and hypoxia. Respiratory infections can be cause by structural changes in the lung and impaired immunity due to sarcoidosis or therapy. Anti-inflammatory therapy alone is not effective in most forms of advanced pulmonary sarcoidosis. New techniques, including high-resolution computer tomography and 18F-fluorodeoxyglucose positron emission tomography (PET) have proved helpful in identifying the cause of advanced disease and directing specific therapy.

Gli stili APA, Harvard, Vancouver, ISO e altri

47

Stanek, Brigitte, e Richard Pacher. "Intravenous therapy for advanced heart failure". Current Opinion in Cardiology 15, n. 3 (maggio 2000): 156–60. http://dx.doi.org/10.1097/00001573-200005000-00006.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Massiou, H. "Book Review: Advanced Therapy of Headache". Cephalalgia 20, n. 2 (marzo 2000): 143. http://dx.doi.org/10.1046/j.1468-2982.2000.00024.x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

49

Low, See-Wei, Justin Z. Lee, Hem Desai, Chiu-Hsieh Hsu, Afshin R. Sam e James L. Knepler. "Endobronchial Valves Therapy for Advanced Emphysema". Journal of Bronchology & Interventional Pulmonology 26, n. 2 (aprile 2019): 81–89. http://dx.doi.org/10.1097/lbr.0000000000000527.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Vitali, Ettore, Tiziano Colombo, Pasquale Fratto, Claudio Russo, Giuseppe Bruschi e Maria Frigerio. "Surgical therapy in advanced heart failure". American Journal of Cardiology 91, n. 9 (maggio 2003): 88–94. http://dx.doi.org/10.1016/s0002-9149(02)03343-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!